Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * ARMISTICE CAPITAL, LLC	2. Date of Event Requiring Statement (MM/DD/YYYY) 7/6/2020	3. Issuer Name and Ticker or Trading Symbol TENAX THERAPEUTICS, INC. [TENX]
(Last)        (First)        (Middle) 510 MADISON AVENUE, 7TH FLOOR,	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          ___X___ 10% Owner _____ Officer (give title below)        _____ Other (specify below)
(Street) NEW YORK, NY 10022       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.0001 par value per share	1523611	D (1)
Common Stock, $0.0001 par value per share	1523611	I	See Footnote 1

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Purchase Warrants	3/13/2020 (2)	9/13/2025	Common Stock	2360313	$1.04	D (1)
Common Stock Purchase Warrants	3/13/2020 (2)	9/13/2025	Common Stock	2360313	$1.04	I	See Footnote (1)
Common Stock Purchase Warrants	12/11/2018 (2)	12/11/2020	Common Stock	2072538	$1.93	D (1)
Common Stock Purchase Warrants	12/11/2018 (2)	12/11/2020	Common Stock	2072538	$1.93	I	See Footnote (1)
Common Stock Purchase Warrants	12/11/2018 (2)	12/11/2023	Common Stock	2072538	$1.93	D (1)
Common Stock Purchase Warrants	12/11/2018 (2)	12/11/2023	Common Stock	2072538	$1.93	I	See Footnote (1)
Pre-Funded Common Stock Purchase Warrants	7/6/2020 (3)	(4)	Common Stock	5260005	$0.0001	D (1)
Pre-Funded Common Stock Purchase Warrants	7/6/2020 (3)	(4)	Common Stock	5260005	$0.0001	I	See Footnote (1)
Series B Common Stock Purchase Warrants	7/6/2020 (3)	1/6/2026	Common Stock	3175924	$0.903	D (1)
Series B Common Stock Purchase Warrants	7/6/2020 (3)	1/6/2026	Common Stock	3175924	$0.903	I	See Footnote (1)
Series C Common Stock Purchase Warrants	7/6/2020 (3)	1/6/2026	Common Stock	4607692	$0.903	D (1)
Series C Common Stock Purchase Warrants	7/6/2020 (3)	1/6/2026	Common Stock	4607692	$0.903	I	See Footnote (1)

Explanation of Responses:
(1)	The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(2)	These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the "Shares") following such exercise.
(3)	These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise.
(4)	These warrants do not expire.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022		X
Armistice Capital Master Fund Ltd. C/O DMS CORPORATE SERVICES LTD. 20 GENESIS CLOSE, P.O. BOX 314 GRAND CAYMAN, E9 KY1-1104		X
Boyd Steven C/O ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022		X

Signatures
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member		7/16/2020
**Signature of Reporting Person		Date
Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd, Director		7/16/2020
**Signature of Reporting Person		Date
/s/ Steven Boyd		7/16/2020
**Signature of Reporting Person		Date